Hospira Announces Voluntary Nationwide Recall of One Lot of 0.5% Marcaine™ (Bupivacaine HCI Injection, USP), 30 ML, Single-Dose, Preservative-Free Vial Due to Visible Particulates

You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

Hospira Announces Voluntary Nationwide Recall of One Lot of 0.5% Marcaine™ (Bupivacaine HCI Injection, USP), 30 ML, Single-Dose, Preservative-Free Vial Due to Visible Particulates

06/17/2014 05:38 PM EDT

Hospira, Inc. (NYSE: HSP), announced today it will initiate a voluntary nationwide recall to the user level for one lot of 0.5% Marcaine™ (Bupivacaine HCl Injection, USP), 30 mL, Single-dose Vial – Preservative Free (NDC 0409-1560-29), Lot 33-545-DD. The recall is due to a confirmed customer report of particulate embedded in the glass vial as well as visible particulate in the solution.

. For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? Please visit subscriberhelp.govdelivery.com
• Other inquiries? webmail@oc.fda.gov

---

This email was sent to filter@clubhouseb.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420